<DOC>
	<DOCNO>NCT02448628</DOCNO>
	<brief_summary>This study multi-center , open label , dose titration , exploratory study evaluate efficacy safety CS-3150 Japanese hypertensive patient moderate renal impairment . Primary endpoint change baseline sit systolic diastolic blood pressure .</brief_summary>
	<brief_title>A Phase 2 Exploratory Study CS-3150 Japanese Hypertensive Patients With Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Men woman Aged 20 year old 80 year young informed consent Subjects hypertension ( Sitting systolic blood pressure SBP &gt; = 140 mmHg &lt; 180 mmHg , Sitting diastolic blood pressure DBP &gt; = 80 mmHg &lt; 110 mmHg ) estimate glomerular filtration rate eGFR &gt; = 30 mL/min/1.73 m2 &lt; 60 mL/min/1.73 m2 Secondary hypertension malignant hypertension Diabetes mellitus albuminuria Serum potassium level &lt; 3.5 &gt; = 5.1 mEq/L Subjects Insulin treatment Subjects preplanned hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>moderate renal impairment</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
	<keyword>CS-3150</keyword>
	<keyword>Japanese</keyword>
</DOC>